IDEAS home Printed from https://ideas.repec.org/p/hhs/ihewps/2022_010.html
   My bibliography  Save this paper

Cancer Care in Türkiye in a European Context

Author

Listed:
  • Hofmarcher, Thomas

    (IHE - The Swedish Institute for Health Economics)

  • Lindgren, Peter

    (IHE - The Swedish Institute for Health Economics)

  • Wilking, Nils

    (IHE - The Swedish Institute for Health Economics)

Abstract

This report explores the state of cancer care in Türkiye. The report builds on a comprehensive analysis of publicly available data and published literature. Drawing on a comparative analysis with three European countries (Belgium, France, Poland), the report describes the disease burden and economic burden of cancer. The report also analyzes three key areas of cancer control: governance, screening, diagnosis and treatment. Based on the analysis, recommendations for future improvements of cancer care in Türkiye are provided. Key findings: • Cancer is the second-leading cause of death and the leading cause of the overall burden of disease in Türkiye • The annual number of new cancer cases in Türkiye could almost double to 400,000 cases until 2040, driven mostly by demographic changes • Cancer survival has improved in Türkiye, yet if survival rates were on par with France, thousands of deaths could be avoided every year • The estimated economic burden of cancer amounted to €2.48 billion or €30 per capita in 2019 Main recommendations: • The governance of cancer care needs a revival • Decision-making in cancer care should be supported by relevant local data • Screening activities need to address awareness challenges in the population • The cancer patient pathway needs to be optimized • Medical staff, treatment facilities, and diagnostic testing need to be geared to future requirements in the provision of modern cancer care • New advances in radiation therapy should be incorporated to free up resources • Patient access to newer cancer medicines is limited in a European context, but could be improved by a stronger consideration of health benefits in relation to costs in decision-making This report was commissioned and funded by Merck Sharp & Dohme (MSD) and based on independent research delivered by IHE. MSD has had no influence or editorial control over the content of this report, and the views and opinions of the authors are not necessarily those of MSD. The report was developed in close alignment with The Economic Policy Research Foundation of Turkey (TEPAV).

Suggested Citation

  • Hofmarcher, Thomas & Lindgren, Peter & Wilking, Nils, 2022. "Cancer Care in Türkiye in a European Context," IHE Report / IHE Rapport 2022:10, IHE - The Swedish Institute for Health Economics.
    • Handle: RePEc:hhs:ihewps:2022_010
    as

    Download full text from publisher

    File URL: https://ihe.se/wp-content/uploads/2022/11/IHE-Report-2022_10_.pdf
    File Function: Full text
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Hofmarcher, Thomas & Lindgren, Peter & Wilking, Nils, 2022. "Diagnosed but not treated: How to improve patient access to advanced NSCLC treatment in Europe," IHE Report / IHE Rapport 2022:2, IHE - The Swedish Institute for Health Economics.
    2. Hofmarcher, Thomas & Keel, George & Lindgren, Peter, 2021. "Cancer care and access to cancer drugs in Asia-Pacific," IHE Report / IHE Rapport 2021:3, IHE - The Swedish Institute for Health Economics, revised 2021.
    3. Li Sun & Rosa Legood & Isabel dos-Santos-Silva & Shivani Mathur Gaiha & Zia Sadique, 2018. "Global treatment costs of breast cancer by stage: A systematic review," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-14, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Michela Franchini & Stefania Pieroni & Edgardo Montrucchio & Jacopo Nori Cucchiari & Cosimo Di Maggio & Enrico Cassano & Brunella Di Nubila & Gian Marco Giuseppetti & Alberto Nicolucci & Gianfranco Sc, 2021. "The P.I.N.K. Study Approach for Supporting Personalized Risk Assessment and Early Diagnosis of Breast Cancer," IJERPH, MDPI, vol. 18(5), pages 1-15, March.
    2. Iasmina Petrovici & Mihaela Ionica & Octavian C. Neagoe, 2021. "Economic Crisis: A Factor for the Delayed Diagnosis of Breast Cancer," IJERPH, MDPI, vol. 18(8), pages 1-10, April.
    3. Manzano, Andrea & Hofmarcher, Thomas, 2023. "Improving the care of women with triple-negative breast cancer," IHE Report / IHE Rapport 2023:2, IHE - The Swedish Institute for Health Economics.
    4. Pousette, Andreas & Hofmarcher, Thomas, 2024. "Tackling inequalities in cancer care in the European Union," IHE Report / IHE Rapport 2024:1, IHE - The Swedish Institute for Health Economics.
    5. Alfredo Palacios & Carlos Rojas-Roque & Lucas González & Ariel Bardach & Agustín Ciapponi & Claudia Peckaitis & Andres Pichon-Riviere & Federico Augustovski, 2021. "Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review," PharmacoEconomics, Springer, vol. 39(5), pages 485-502, May.
    6. Lorna Wills & Diana Nagarwalla & Clare Pearson & Sean McPhail & Rose Hinchliffe & Ben Sharpless & Fahmina Fardus-Reid & Lyndsy Ambler & Samantha Harrison & Jon Shelton, 2024. "Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(5), pages 763-774, July.
    7. Ian Grady & Sean Grady & Nailya Chanisheva, 2021. "Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1365-1370, December.
    8. Francesco Saverio Mennini & Marco Trabucco Aurilio & Simone Gazzillo & Claudia Nardone & Paolo Sciattella & Andrea Marcellusi & Raffaele Migliorini & Valerio Sciannamea & Andrea Piccioni & Matteo Bolc, 2021. "An Analysis of the Social and Economic Costs of Breast Cancer in Italy," IJERPH, MDPI, vol. 18(17), pages 1-12, August.
    9. Chunhuan Lao & Mohana Mondal & Marion Kuper-Hommel & Ian Campbell & Ross Lawrenson, 2022. "Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand," PharmacoEconomics - Open, Springer, vol. 6(4), pages 539-548, July.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hhs:ihewps:2022_010. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Annette Persson Dietmann (email available below). General contact details of provider: https://ihe.se/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.